Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 230

1.

Rapalog combined with CCR4 antagonist improves anticancer vaccines efficacy.

Beziaud L, Boullerot L, Tran T, Mansi L, Marie-Joseph EL, Ravel P, Johannes L, Bayry J, Tartour E, Adotévi O.

Int J Cancer. 2018 Sep 5. doi: 10.1002/ijc.31842. [Epub ahead of print]

PMID:
30183073
2.

Resident memory T cells, critical components in tumor immunology.

Mami-Chouaib F, Blanc C, Corgnac S, Hans S, Malenica I, Granier C, Tihy I, Tartour E.

J Immunother Cancer. 2018 Sep 4;6(1):87. doi: 10.1186/s40425-018-0399-6. Review.

3.

Targeting Resident Memory T Cells for Cancer Immunotherapy.

Blanc C, Hans S, Tran T, Granier C, Saldman A, Anson M, Oudard S, Tartour E.

Front Immunol. 2018 Jul 27;9:1722. doi: 10.3389/fimmu.2018.01722. eCollection 2018. Review.

4.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
5.

Therapeutic cancer vaccine: building the future from lessons of the past.

Tran T, Blanc C, Granier C, Saldmann A, Tanchot C, Tartour E.

Semin Immunopathol. 2018 Jul 5. doi: 10.1007/s00281-018-0691-z. [Epub ahead of print] Review.

PMID:
29978248
6.

HPV RNA CISH score identifies two prognostic groups in a p16 positive oropharyngeal squamous cell carcinoma population.

Augustin J, Mandavit M, Outh-Gauer S, Grard O, Gasne C, Lépine C, Mirghani H, Hans S, Bonfils P, Denize T, Bruneval P, Bishop JA, Fontugne J, Péré H, Tartour E, Badoual C.

Mod Pathol. 2018 Jun 20. doi: 10.1038/s41379-018-0090-y. [Epub ahead of print]

PMID:
29925856
7.

Evaluation of the efficacy of the 4 tests (p16 immunochemistry, polymerase chain reaction, DNA, and RNA in situ hybridization) to evaluate a human papillomavirus infection in head and neck cancers: a cohort of 348 French squamous cell carcinomas.

Augustin J, Outh-Gauer S, Mandavit M, Gasne C, Grard O, Denize T, Nervo M, Mirghani H, Laccourreye O, Bonfils P, Bruneval P, Veyer D, Péré H, Tartour E, Badoual C.

Hum Pathol. 2018 Aug;78:63-71. doi: 10.1016/j.humpath.2018.04.006. Epub 2018 Apr 22.

PMID:
29684499
8.

Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells.

Granier C, Vinatier E, Colin E, Mandavit M, Dariane C, Verkarre V, Biard L, El Zein R, Lesaffre C, Galy-Fauroux I, Roussel H, De Guillebon E, Blanc C, Saldmann A, Badoual C, Gey A, Tartour É.

J Vis Exp. 2018 Feb 8;(132). doi: 10.3791/56606.

PMID:
29553498
9.

Immunotherapy in head and neck cancers: A new challenge for immunologists, pathologists and clinicians.

Outh-Gauer S, Alt M, Le Tourneau C, Augustin J, Broudin C, Gasne C, Denize T, Mirghani H, Fabre E, Ménard M, Scotte F, Tartour E, Badoual C.

Cancer Treat Rev. 2018 Apr;65:54-64. doi: 10.1016/j.ctrv.2018.02.008. Epub 2018 Mar 1. Review.

PMID:
29547766
10.

[Tim-3: a novel biomarker and therapeutic target in oncology].

Granier C, Gey A, Dariane C, Mejean A, Timsit MO, Blanc C, Verkarre V, Radulescu C, Fabre E, Vano Y, Oudard S, Badoual C, Tartour É.

Med Sci (Paris). 2018 Mar;34(3):231-237. doi: 10.1051/medsci/20183403011. Epub 2018 Mar 16. French.

PMID:
29547109
11.

Transplantation of Human Embryonic Stem Cell-Derived Cardiovascular Progenitors for Severe Ischemic Left Ventricular Dysfunction.

Menasché P, Vanneaux V, Hagège A, Bel A, Cholley B, Parouchev A, Cacciapuoti I, Al-Daccak R, Benhamouda N, Blons H, Agbulut O, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Charron D, Tartour E, Tachdjian G, Desnos M, Larghero J.

J Am Coll Cardiol. 2018 Jan 30;71(4):429-438. doi: 10.1016/j.jacc.2017.11.047.

PMID:
29389360
12.

New therapeutic targets in the inflammatory microenvironment.

Tartour E.

ESMO Open. 2018 Jan 13;3(1):e000310. doi: 10.1136/esmoopen-2017-000310. eCollection 2018. No abstract available.

13.

Tissue-resident memory T cells play a key role in the efficacy of cancer vaccines.

Granier C, Blanc C, Karaki S, Tran T, Roussel H, Tartour E.

Oncoimmunology. 2017 Aug 8;6(11):e1358841. doi: 10.1080/2162402X.2017.1358841. eCollection 2017.

14.

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer.

Granier C, De Guillebon E, Blanc C, Roussel H, Badoual C, Colin E, Saldmann A, Gey A, Oudard S, Tartour E.

ESMO Open. 2017 Jul 3;2(2):e000213. doi: 10.1136/esmoopen-2017-000213. eCollection 2017. Review.

15.

Synthetic melanin bound to subunit vaccine antigens significantly enhances CD8+ T-cell responses.

Carpentier AF, Geinguenaud F, Tran T, Sejalon F, Martin A, Motte L, Tartour E, Banissi C.

PLoS One. 2017 Jul 17;12(7):e0181403. doi: 10.1371/journal.pone.0181403. eCollection 2017.

16.

Induction of resident memory T cells enhances the efficacy of cancer vaccine.

Nizard M, Roussel H, Diniz MO, Karaki S, Tran T, Voron T, Dransart E, Sandoval F, Riquet M, Rance B, Marcheteau E, Fabre E, Mandavit M, Terme M, Blanc C, Escudie JB, Gibault L, Barthes FLP, Granier C, Ferreira LCS, Badoual C, Johannes L, Tartour E.

Nat Commun. 2017 May 24;8:15221. doi: 10.1038/ncomms15221.

17.

Composite biomarkers defined by multiparametric immunofluorescence analysis identify ALK-positive adenocarcinoma as a potential target for immunotherapy.

Roussel H, De Guillebon E, Biard L, Mandavit M, Gibault L, Fabre E, Antoine M, Hofman P, Beau-Faller M, Blons H, Danel C, Barthes FLP, Gey A, Granier C, Wislez M, Laurent-Puig P, Oudard S, Bruneval P, Badoual C, Cadranel J, Tartour E.

Oncoimmunology. 2017 Feb 21;6(4):e1286437. doi: 10.1080/2162402X.2017.1286437. eCollection 2017.

18.

Immunomodulatory Activity of VEGF in Cancer.

Lapeyre-Prost A, Terme M, Pernot S, Pointet AL, Voron T, Tartour E, Taieb J.

Int Rev Cell Mol Biol. 2017;330:295-342. doi: 10.1016/bs.ircmb.2016.09.007. Epub 2016 Dec 26. Review.

PMID:
28215534
19.

[The "immune checkpoints", how does it work].

Granier C, Soumelis V, Mandavit M, Gibault L, Belazzoug R, de Guillebon E, Badoual C, Tartour E, Roussel H.

Ann Pathol. 2017 Feb;37(1):18-28. doi: 10.1016/j.annpat.2016.12.007. Epub 2017 Feb 1. French.

PMID:
28160999
20.

[Immunotherapy in uropathology].

Verkarre V, Roussel H, Granier C, Tartour E, Allory Y.

Ann Pathol. 2017 Feb;37(1):90-100. doi: 10.1016/j.annpat.2016.12.015. Epub 2017 Jan 19. Review. French.

PMID:
28111042
21.

[Current events in immunotherapy for upper aerodigestive tract cancer].

Outh-Gauer S, Le Tourneau C, Broudin C, Scotte F, Roussel H, Hans S, Mandavit M, Tartour E, Badoual C.

Ann Pathol. 2017 Feb;37(1):79-89. doi: 10.1016/j.annpat.2016.12.013. Epub 2017 Jan 19. Review. French.

PMID:
28111039
22.

Biomarqueurs prédictifs de réponse aux traitements bloquant les voies de costimulation inhibitrices.

Pagès F, Granier C, Kirilovsky A, Elsissy C, Tartour E.

Bull Cancer. 2016 Nov;103 Suppl 1:S151-S159. doi: 10.1016/S0007-4551(16)30373-3. Review. French.

PMID:
28057179
23.

Immunothérapie dans les cancers de la prostate.

Oudard S, Thibault C, Angelergues A, Tartour E, Timsit MO, Mejean A, Michel C, Vano Y.

Bull Cancer. 2016 Nov;103 Suppl 1:S144-S150. doi: 10.1016/S0007-4551(16)30372-1. French.

PMID:
28057178
24.

L’immunothérapie des cancers : de l’espoir à la réalité.

Pagès F, Bay JO, Tartour E.

Bull Cancer. 2016 Nov;103 Suppl 1:S119-S121. doi: 10.1016/S0007-4551(16)30367-8. French. No abstract available.

PMID:
28057173
25.

Sunitinib in kidney cancer: 10 years of experience and development.

Nassif E, Thibault C, Vano Y, Fournier L, Mauge L, Verkarre V, Timsit MO, Mejean A, Tartour E, Oudard S.

Expert Rev Anticancer Ther. 2017 Feb;17(2):129-142. doi: 10.1080/14737140.2017.1272415. Epub 2016 Dec 27. Review.

PMID:
27967249
26.

Prognostic Value of Baseline Neutrophil-to-Lymphocyte Ratio in Metastatic Urothelial Carcinoma Patients Treated With First-line Chemotherapy: A Large Multicenter Study.

Auvray M, Elaidi R, Ozguroglu M, Guven S, Gauthier H, Culine S, Caty A, Dujardin C, Auclin E, Thibaut C, Combe P, Tartour E, Oudard S.

Clin Genitourin Cancer. 2017 Jun;15(3):e469-e476. doi: 10.1016/j.clgc.2016.10.013. Epub 2016 Nov 16.

PMID:
27964892
27.

Tim-3 Expression on Tumor-Infiltrating PD-1+CD8+ T Cells Correlates with Poor Clinical Outcome in Renal Cell Carcinoma.

Granier C, Dariane C, Combe P, Verkarre V, Urien S, Badoual C, Roussel H, Mandavit M, Ravel P, Sibony M, Biard L, Radulescu C, Vinatier E, Benhamouda N, Peyromaure M, Oudard S, Méjean A, Timsit MO, Gey A, Tartour E.

Cancer Res. 2017 Mar 1;77(5):1075-1082. doi: 10.1158/0008-5472.CAN-16-0274. Epub 2016 Nov 21.

28.

Is There Still Room for Cancer Vaccines at the Era of Checkpoint Inhibitors.

Karaki S, Anson M, Tran T, Giusti D, Blanc C, Oudard S, Tartour E.

Vaccines (Basel). 2016 Nov 3;4(4). pii: E37. Review.

29.

Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Vacchelli E, Bloy N, Aranda F, Buqué A, Cremer I, Demaria S, Eggermont A, Formenti SC, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Jul 25;5(9):e1214790. eCollection 2016. Review.

30.

Enterococcus hirae and Barnesiella intestinihominis Facilitate Cyclophosphamide-Induced Therapeutic Immunomodulatory Effects.

Daillère R, Vétizou M, Waldschmitt N, Yamazaki T, Isnard C, Poirier-Colame V, Duong CPM, Flament C, Lepage P, Roberti MP, Routy B, Jacquelot N, Apetoh L, Becharef S, Rusakiewicz S, Langella P, Sokol H, Kroemer G, Enot D, Roux A, Eggermont A, Tartour E, Johannes L, Woerther PL, Chachaty E, Soria JC, Golden E, Formenti S, Plebanski M, Madondo M, Rosenstiel P, Raoult D, Cattoir V, Boneca IG, Chamaillard M, Zitvogel L.

Immunity. 2016 Oct 18;45(4):931-943. doi: 10.1016/j.immuni.2016.09.009. Epub 2016 Oct 4.

31.

In Silico Adjuvant Design and Validation.

Davies MN, Pere H, Bosschem I, Haesebrouck F, Flahou B, Tartour E, Flower DR, Tough DF, Bayry J.

Methods Mol Biol. 2017;1494:107-125.

PMID:
27718189
32.

Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma.

Guillot-Delost M, Guilleré L, Berger F, Ventre A, Michea P, Sirven P, Pattarini L, Scholer-Dahirel A, Kebir FZ, Huerre M, Chouchane-Mlik O, Lappartient E, Rodriguez J, Jouffroy T, Klijanienko J, Nicolas A, Sastre-Garau X, Honorio S, Mosseri V, Le Peltier N, Sablin MP, Le Tourneau C, Tartour É, Badoual C, Soumelis V.

Oncoimmunology. 2016 Jun 7;5(7):e1179414. doi: 10.1080/2162402X.2016.1179414. eCollection 2016 Jul.

33.

Intra-cheek immunization as a novel vaccination route for therapeutic vaccines of head and neck squamous cell carcinomas using plasmo virus-like particles.

Macedo R, Rochefort J, Guillot-Delost M, Tanaka K, Le Moignic A, Noizat C, Baillou C, Mateo V, Carpentier AF, Tartour E, Bertolus C, Bellier B, Lescaille G, Lemoine FM.

Oncoimmunology. 2016 Jul 6;5(7):e1164363. doi: 10.1080/2162402X.2016.1164363. eCollection 2016 Jul.

34.

Engineered mesenchymal stem cells as vectors in a suicide gene therapy against preclinical murine models for solid tumors.

Amara I, Pramil E, Senamaud-Beaufort C, Devillers A, Macedo R, Lescaille G, Seguin J, Tartour E, Lemoine FM, Beaune P, de Waziers I.

J Control Release. 2016 Oct 10;239:82-91. doi: 10.1016/j.jconrel.2016.08.019. Epub 2016 Aug 23.

PMID:
27565211
35.

Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.

Buqué A, Bloy N, Aranda F, Cremer I, Eggermont A, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2016 Mar 10;5(6):e1149674. doi: 10.1080/2162402X.2016.1149674. eCollection 2016 Jun. Review.

36.

Immunoprevalence and magnitude of HLA-DP4 versus HLA-DR-restricted spontaneous CD4(+) Th1 responses against telomerase in cancer patients.

Laheurte C, Galaine J, Beziaud L, Dosset M, Kerzerho J, Jacquemard C, Gaugler B, Ferrand C, Dormoy A, Aubin F, Jacoulet P, Westeel V, Borg C, Tartour E, Godet Y, Maillère B, Adotévi O.

Oncoimmunology. 2016 Feb 18;5(5):e1137416. doi: 10.1080/2162402X.2015.1137416. eCollection 2016 May.

37.

[Cancer immunotherapy: Rational and recent breakthroughs].

Granier C, Karaki S, Roussel H, Badoual C, Tran T, Anson M, Fabre E, Oudard S, Tartour E.

Rev Med Interne. 2016 Oct;37(10):694-700. doi: 10.1016/j.revmed.2016.05.023. Epub 2016 Jun 28. Review. French.

PMID:
27370898
38.

IL-15 Trans-Signaling with the Superagonist RLI Promotes Effector/Memory CD8+ T Cell Responses and Enhances Antitumor Activity of PD-1 Antagonists.

Desbois M, Le Vu P, Coutzac C, Marcheteau E, Béal C, Terme M, Gey A, Morisseau S, Teppaz G, Boselli L, Jacques Y, Béchard D, Tartour E, Cassard L, Chaput N.

J Immunol. 2016 Jul 1;197(1):168-78. doi: 10.4049/jimmunol.1600019. Epub 2016 May 23.

39.

Rapalogs Efficacy Relies on the Modulation of Antitumor T-cell Immunity.

Beziaud L, Mansi L, Ravel P, Marie-Joseph EL, Laheurte C, Rangan L, Bonnefoy F, Pallandre JR, Boullerot L, Gamonet C, Vrecko S, Queiroz L, Maurina T, Mouillet G, Hon TN, Curtit E, Royer B, Gaugler B, Bayry J, Tartour E, Thiery-Vuillemin A, Pivot X, Borg C, Godet Y, Adotévi O.

Cancer Res. 2016 Jul 15;76(14):4100-12. doi: 10.1158/0008-5472.CAN-15-2452. Epub 2016 May 17.

40.

A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.

Tran T, Diniz MO, Dransart E, Gey A, Merillon N, Lone YC, Godefroy S, Sibley C, Ferreira LC, Medioni J, Oudard S, Johannes L, Tartour E.

Clin Cancer Res. 2016 Aug 15;22(16):4133-44. doi: 10.1158/1078-0432.CCR-16-0044. Epub 2016 Mar 22.

41.

Hope in the Long Road Toward the Development of a Therapeutic Human Papillomavirus Vaccine.

Karaki S, Pere H, Badoual C, Tartour E.

Clin Cancer Res. 2016 May 15;22(10):2317-9. doi: 10.1158/1078-0432.CCR-16-0216. Epub 2016 Mar 11.

42.

Resident Memory T Cells as Surrogate Markers of the Efficacy of Cancer Vaccines.

Nizard M, Roussel H, Tartour E.

Clin Cancer Res. 2016 Feb 1;22(3):530-2. doi: 10.1158/1078-0432.CCR-15-2364. Epub 2015 Nov 5.

43.

Smoking and the Association Between Depressive Symptoms and Absolute Neutrophil Count in the Investigations Préventives et Cliniques Cohort Study.

Vulser H, Wiernik E, Tartour E, Thomas F, Pannier B, Czernichow S, Hanon O, Simon T, Simon JM, Ducolombier C, Consoli SM, Danchin N, Limosin F, Lemogne C.

Psychosom Med. 2015 Nov-Dec;77(9):1039-49. doi: 10.1097/PSY.0000000000000243.

PMID:
26461856
44.

Trial Watch: Adoptive cell transfer for oncological indications.

Aranda F, Buqué A, Bloy N, Castoldi F, Eggermont A, Cremer I, Fridman WH, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 May 5;4(11):e1046673. eCollection 2015 Nov. Review.

45.

Immunogenicity and Safety of Influenza Vaccine in Inflammatory Bowel Disease Patients Treated or not with Immunomodulators and/or Biologics: A Two-year Prospective Study.

Launay O, Abitbol V, Krivine A, Slama LB, Bourreille A, Dupas JL, Hébuterne X, Savoye G, Deplanque D, Bouhnik Y, Pelletier AL, Galtier F, Laharie D, Nachury M, Zerbib F, Allez M, Bommelaer G, Duclos B, Lucht F, Gougeon ML, Tartour E, Rozenberg F, Hanslik T, Beaugerie L, Carrat F; MICIVAX Study Group.

J Crohns Colitis. 2015 Dec;9(12):1096-107. doi: 10.1093/ecco-jcc/jjv152. Epub 2015 Sep 7.

PMID:
26351392
46.

Vaccine-induced tumor regression requires a dynamic cooperation between T cells and myeloid cells at the tumor site.

Thoreau M, Penny HL, Tan K, Regnier F, Weiss JM, Lee B, Johannes L, Dransart E, Le Bon A, Abastado JP, Tartour E, Trautmann A, Bercovici N.

Oncotarget. 2015 Sep 29;6(29):27832-46. doi: 10.18632/oncotarget.4940.

47.

Trial watch: Naked and vectored DNA-based anticancer vaccines.

Bloy N, Buqué A, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Apr 2;4(5):e1026531. eCollection 2015 May.

48.

Trial Watch: Therapeutic vaccines in metastatic renal cell carcinoma.

Combe P, de Guillebon E, Thibault C, Granier C, Tartour E, Oudard S.

Oncoimmunology. 2015 Mar 19;4(5):e1001236. eCollection 2015 May. Review.

49.

Consensus nomenclature for CD8+ T cell phenotypes in cancer.

Apetoh L, Smyth MJ, Drake CG, Abastado JP, Apte RN, Ayyoub M, Blay JY, Bonneville M, Butterfield LH, Caignard A, Castelli C, Cavallo F, Celis E, Chen L, Colombo MP, Comin-Anduix B, Coukos G, Dhodapkar MV, Dranoff G, Frazer IH, Fridman WH, Gabrilovich DI, Gilboa E, Gnjatic S, Jäger D, Kalinski P, Kaufman HL, Kiessling R, Kirkwood J, Knuth A, Liblau R, Lotze MT, Lugli E, Marincola F, Melero I, Melief CJ, Mempel TR, Mittendorf EA, Odun K, Overwijk WW, Palucka AK, Parmiani G, Ribas A, Romero P, Schreiber RD, Schuler G, Srivastava PK, Tartour E, Valmori D, van der Burg SH, van der Bruggen P, van den Eynde BJ, Wang E, Zou W, Whiteside TL, Speiser DE, Pardoll DM, Restifo NP, Anderson AC.

Oncoimmunology. 2015 Feb 25;4(4):e998538. eCollection 2015 Apr.

50.

Trial Watch: Peptide-based anticancer vaccines.

Pol J, Bloy N, Buqué A, Eggermont A, Cremer I, Sautès-Fridman C, Galon J, Tartour E, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2015 Jan 9;4(4):e974411. eCollection 2015 Apr. Review.

Supplemental Content

Loading ...
Support Center